Objectif
Synapse Information (UK) have developed a novel semantic web technology, SEQUOIA – Semantic Query of Information Assets – allowing users to rapidly question > 100 disparate data assets in a code-free spreadsheet environment. Having proved the core platform functionality within the financial sector, Synapse now seek to apply SEQUOIA to the field of drug discovery R&D.
New drugs are required urgently to treat cancers & other rare/neurological diseases. However, costs and timescales of drug development are huge due to high failure rates. A principle barrier is the lack of real time comparison of disparate datasets, which can identify causal correlations behind reactions throughout the R&D process. Building on the prototype kernel solution, SEQUOIA targets the many high performance silos of public online drug R&D data, enabling all researchers to semantically probe these ontologies against internal R&D. Synapse therefore aim to catalyse a strategic 10 - 100× productivity gain during the discovery phase to disrupt the €5.5 billion/yr drug discovery software market.
The overall project aims to: fulfil the further technical developments required to transfer SEQUOIA into priority sectors within drug R&D; initiate the technical and commercial partnerships with key stakeholders in the pharmaceutical industry; validate performance through extended field trials; establish regulatory compliance; deliver compatibility with key user data environments; and optimise a developed product.
The proposed Phase 1 feasibility study seeks to address these requirements through: delivery of an elaborated business plan; prioritised EU market entry strategy; analysis of market-held data assets, technical development roadmap; engagement of key stakeholders in the pharmaceutical industry; supply chain initiation; development of IP strategy and value model; as well as regulatory and legal roadmaps for the final phase of developments and exploitation.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencescomputer and information sciencesknowledge engineeringontology
- natural sciencescomputer and information sciencessoftware
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- natural sciencescomputer and information sciencesinternetsemantic web
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
B3 1EH BIRMINGHAM
Royaume-Uni
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.